Morgan Stanley raised the firm’s price target on United Therapeutics (UTHR) to $471 from $447 and keeps an Equal Weight rating on the shares following mixed Q4 results, stating that the post-earnings move up in shares was driven by the announcement of a soft mist formulation of TRE with a potential 2027 launch and continued confidence in Tyvaso TETON-1 IPF and Ralinepag for PAH.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $466 from $423 at Wells Fargo
- Balancing Franchise Headwinds and Pipeline Upside: Rationale Behind a Hold on United Therapeutics
- United Therapeutics price target raised to $569 from $546 at BofA
- RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind
- Leerink sees MannKind selloff as ‘overreaction’ to headline news